
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diagnostics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Diagnostics (Basel)</journal-id><journal-id journal-id-type="publisher-id">diagnostics</journal-id><journal-title-group><journal-title>Diagnostics</journal-title></journal-title-group><issn pub-type="epub">2075-4418</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">33260566</article-id><article-id pub-id-type="pmc">7761307</article-id><article-id pub-id-type="doi">10.3390/diagnostics10121022</article-id><article-id pub-id-type="publisher-id">diagnostics-10-01022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Systematic Review of Pharmacologic and Rehabilitative Treatment of Small Fiber Neuropathies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vecchio</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="af1-diagnostics-10-01022">1</xref><xref ref-type="aff" rid="af2-diagnostics-10-01022">2</xref><xref rid="c1-diagnostics-10-01022" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1256-7605</contrib-id><name><surname>Chiaramonte</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="af1-diagnostics-10-01022">1</xref><xref rid="c1-diagnostics-10-01022" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7991-6182</contrib-id><name><surname>Romano</surname><given-names>Marcello</given-names></name><xref ref-type="aff" rid="af3-diagnostics-10-01022">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5600-9560</contrib-id><name><surname>Pavone</surname><given-names>Piero</given-names></name><xref ref-type="aff" rid="af4-diagnostics-10-01022">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8260-8890</contrib-id><name><surname>Musumeci</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="af5-diagnostics-10-01022">5</xref><xref ref-type="aff" rid="af6-diagnostics-10-01022">6</xref><xref ref-type="aff" rid="af7-diagnostics-10-01022">7</xref></contrib><contrib contrib-type="author"><name><surname>Mauro</surname><given-names>Giulia Letizia</given-names></name><xref ref-type="aff" rid="af8-diagnostics-10-01022">8</xref></contrib></contrib-group><aff id="af1-diagnostics-10-01022"><label>1</label>Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, 95123 Catania, Italy</aff><aff id="af2-diagnostics-10-01022"><label>2</label>Rehabilitation Unit, &#x0201c;AOU Policlinico Vittorio Emanuele&#x0201d;, 95123 Catania, Italy</aff><aff id="af3-diagnostics-10-01022"><label>3</label>Neurology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, 90146 Palermo, Italy; <email>mc.romano1958@gmail.com</email></aff><aff id="af4-diagnostics-10-01022"><label>4</label>Department of General Paediatrics A.O.U., Policlinico-Vittorio Emanuele University Hospital, 95123 Catania, Italy; <email>ppavone@unict.it</email></aff><aff id="af5-diagnostics-10-01022"><label>5</label>Department of Biomedical and Biotechnological Sciences, Anatomy, Histology and Movement Science Section, School of Medicine, University of Catania, 95123 Catania, Italy; <email>g.musumeci@unict.it</email></aff><aff id="af6-diagnostics-10-01022"><label>6</label>Research Center of Motor Activities (CRAM), University of Catania, 95123 Catania, Italy</aff><aff id="af7-diagnostics-10-01022"><label>7</label>Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA</aff><aff id="af8-diagnostics-10-01022"><label>8</label>Department of Surgical and Oncology Sciences, University of Palermo, 90127 Palermo, Italy; <email>giulia.letiziamauro@unipa.it</email></aff><author-notes><corresp id="c1-diagnostics-10-01022"><label>*</label>Correspondence: <email>michele.vecchio@unict.it</email> (M.V.); <email>ritachiaramd@gmail.com</email> (R.C.); Tel.: +39-(0)3782703 (M.V.)</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><elocation-id>1022</elocation-id><history><date date-type="received"><day>26</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The aim of this systematic review is to guide the physician in defining the pharmacologic and rehabilitative therapeutic approaches for adopting the best strategies described in the current literature. The search was conducted in PubMed, EMBASE, Cochrane Library and Web of Science to identify the treatment of small fiber neuropathies. Two reviewers independently reviewed and came to a consensus on which articles met inclusion/exclusion criteria. The authors excluded the duplicates, animal studies and included the English articles in which the treatment of patients with small fiber neuropathies was described. The search identified a total of 975 articles with the keywords &#x0201c;small fiber neuropathy&#x0201d; AND &#x0201c;rehabilitation&#x0201d; OR &#x0201c;therapy&#x0201d; OR &#x0201c;treatment&#x0201d;. Seventy-eight selected full-text were analyzed by the reviewers. Forty-two publications met the inclusion criteria and were included in the systematic review to describe the rehabilitative and pharmacologic treatment of small fiber neuropathies. Despite the range of different protocols of treatment for small fiber neuropathy, other robust trials are needed. In addition, always different therapeutic approaches are used; a unique protocol could be important for the clinicians. More research is needed to build evidence for the best strategy and to delineate a definitive therapeutic protocol.</p></abstract><kwd-group><kwd>small fiber neuropathy</kwd><kwd>treatment</kwd><kwd>systematic reviews</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-diagnostics-10-01022"><title>1. Introduction</title><sec><title>Small Fiber Neuropathy</title><p>Small fiber neuropathy (SFN) is caused by the impairment of unmyelinated C and thinly myelinated A&#x003b4; fibers. The symptoms are characterized by sensory symptoms, pain and autonomic symptoms, such as palpitations, gastrointestinal disturbances, and orthostatic dizziness. Neuropathic symptoms have a negative impact on the quality of life [<xref rid="B1-diagnostics-10-01022" ref-type="bibr">1</xref>]. The symptoms and signs can be present as spontaneous (e.g., burning, deep, itching and paroxysmal) or evoked (e.g., thermal allodynia, light tough allodynia and hyperalgesia) pain.</p><p>Our systematic review defined the different rehabilitative and pharmacological approaches for SFN and to guide the physician to delineate a therapeutic protocol adopting the best strategies described in the current literature. In addition, we analyzed all the therapeutic approaches we found in the current literature to realize a guide to provide a common language to the multidisciplinary team such as physiatrists, neurologists, physiotherapists, nurses and neuropsychologists that must treat this disorder. The current literature did not describe a unique therapeutic approach, use arbitrarily different therapies. A therapeutic protocol should make more objective, reproducible, repeatable the outcomes and could help the multidisciplinary team to manage the patients.</p></sec></sec><sec sec-type="methods" id="sec2-diagnostics-10-01022"><title>2. Methods</title><sec id="sec2dot1-diagnostics-10-01022"><title>2.1. Search Strategy</title><p>The search was carried out on the following medical electronic databases: PubMed, EMBASE, Cochrane Library and Scopus, Web of Science. The reference list of the related articles was also used to search for other suitable documents. The review was conducted from 22 May 2020 to 1 July 2020.</p></sec><sec id="sec2dot2-diagnostics-10-01022"><title>2.2. Selection Criteria and Data Extraction</title><p>Studies considered for this review must include the therapeutic methods in patients with SFN. We included English original articles about the rehabilitation and the pharmacological approaches for the SFN. We excluded animal studies, participants with other neuropathies. We also excluded all of the remaining duplicates.</p><p>Two reviewers (C.R. and V.M.) independently screened the titles and abstracts from the initial search to identify relevant records and to identify eligible studies based on title and abstract. Selected full texts were then reviewed and included in the systematic review, following the PRISMA protocol [<xref rid="B2-diagnostics-10-01022" ref-type="bibr">2</xref>] and in accordance with the PICOS (population, intervention, comparison, outcome, and study design) criteria [<xref rid="B3-diagnostics-10-01022" ref-type="bibr">3</xref>] shown in <xref rid="diagnostics-10-01022-t001" ref-type="table">Table 1</xref>: Participants were all patients affected by SFN; intervention was based on rehabilitation therapy or pharmacological approaches; the comparator was any comparator; the outcomes included clinical assessments, diagnostic scales, electromyography and nerve conduction, biopsy; and study design was randomized clinical trials (RCTs), case series and case report, retrospective studies.</p></sec></sec><sec sec-type="results" id="sec3-diagnostics-10-01022"><title>3. Results</title><sec id="sec3dot1-diagnostics-10-01022"><title>3.1. Description of the Studies</title><p>From 1984 to 2019, the database search of 975 articles with the following MeSH terms, words and combinations of words &#x0201c;small fiber neuropathy&#x0201d; AND &#x0201c;rehabilitation&#x0201d; OR &#x0201c;therapy&#x0201d; OR &#x0201c;treatment&#x0201d;, whose titles and abstracts were screened by the reviewers. The papers that remained for full-text screening were 78, and the eligibility of the study inclusion was assessed independently. Forty-two publications met the inclusion criteria and were included in the systematic review. Thirty-six were excluded for the following reasons: 18 involved individuals with different disorders from SFN, 6 examined different topics from our aim, 12 did not present any therapeutic procedure (<xref ref-type="fig" rid="diagnostics-10-01022-f001">Figure 1</xref>).</p><p>The qualitative information synthesis for each parameter was attributed to the following evidence levels according to the recommendations of the Oxford Center for Evidence-Based Medicine: evidence from a systematic review of randomized controlled trials (1a), controlled clinical studies (2a), case&#x02013;control-studies (3a) and from non-systematic reviews (4) (<xref rid="diagnostics-10-01022-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot2-diagnostics-10-01022"><title>3.2. Variations of Experimental Conditions across the Studies</title><p>The selected 42 articles were described on the basis of the several therapeutic methods used in each study for the treatment of SFN. Characteristics of the studies are shown in <xref rid="diagnostics-10-01022-t001" ref-type="table">Table 1</xref>.</p><p>All study groups were not homogeneous for relevant general clinical features as clinical presentation, duration of disease and of the symptoms, kinds of diagnostic measures, the severity of symptoms, rehabilitation and pharmacological therapy, time of starting therapy, duration of treatment, the follow-up period at the end of the therapy (<xref rid="diagnostics-10-01022-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot3-diagnostics-10-01022"><title>3.3. Pharmacologic and Rehabilitation Therapy</title><p>Many different treatments were experienced. Opioid analgesics [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>,<xref rid="B21-diagnostics-10-01022" ref-type="bibr">21</xref>,<xref rid="B24-diagnostics-10-01022" ref-type="bibr">24</xref>] or nonopioid analgesic [<xref rid="B22-diagnostics-10-01022" ref-type="bibr">22</xref>,<xref rid="B26-diagnostics-10-01022" ref-type="bibr">26</xref>], corticosteroids [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>,<xref rid="B10-diagnostics-10-01022" ref-type="bibr">10</xref>,<xref rid="B33-diagnostics-10-01022" ref-type="bibr">33</xref>,<xref rid="B34-diagnostics-10-01022" ref-type="bibr">34</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>,<xref rid="B44-diagnostics-10-01022" ref-type="bibr">44</xref>], intravenous immunoglobulin (IVIG) alone [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>,<xref rid="B12-diagnostics-10-01022" ref-type="bibr">12</xref>,<xref rid="B15-diagnostics-10-01022" ref-type="bibr">15</xref>,<xref rid="B23-diagnostics-10-01022" ref-type="bibr">23</xref>,<xref rid="B27-diagnostics-10-01022" ref-type="bibr">27</xref>,<xref rid="B31-diagnostics-10-01022" ref-type="bibr">31</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>,<xref rid="B39-diagnostics-10-01022" ref-type="bibr">39</xref>,<xref rid="B46-diagnostics-10-01022" ref-type="bibr">46</xref>,<xref rid="B47-diagnostics-10-01022" ref-type="bibr">47</xref>] or in combination with other specific drugs, such as azathioprine [<xref rid="B29-diagnostics-10-01022" ref-type="bibr">29</xref>], anti-epileptic drugs [<xref rid="B4-diagnostics-10-01022" ref-type="bibr">4</xref>,<xref rid="B11-diagnostics-10-01022" ref-type="bibr">11</xref>,<xref rid="B13-diagnostics-10-01022" ref-type="bibr">13</xref>,<xref rid="B16-diagnostics-10-01022" ref-type="bibr">16</xref>,<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>,<xref rid="B28-diagnostics-10-01022" ref-type="bibr">28</xref>,<xref rid="B32-diagnostics-10-01022" ref-type="bibr">32</xref>], immunotherapy [<xref rid="B14-diagnostics-10-01022" ref-type="bibr">14</xref>,<xref rid="B19-diagnostics-10-01022" ref-type="bibr">19</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>], hormone therapy [<xref rid="B7-diagnostics-10-01022" ref-type="bibr">7</xref>,<xref rid="B43-diagnostics-10-01022" ref-type="bibr">43</xref>]. Less used are the following therapeutic strategies, in used for specific disorders, such as ARA290, an erythropoietin derivate for sarcoidosis SFN [<xref rid="B45-diagnostics-10-01022" ref-type="bibr">45</xref>], recombinant human nerve growth factor for diabetic SFN [<xref rid="B5-diagnostics-10-01022" ref-type="bibr">5</xref>], propranolol for SFN related to aquagenic pruritus [<xref rid="B9-diagnostics-10-01022" ref-type="bibr">9</xref>], plasma exchange therapy for complex regional pain syndrome [<xref rid="B6-diagnostics-10-01022" ref-type="bibr">6</xref>], enzyme replacement therapy for Fabry related SFN [<xref rid="B17-diagnostics-10-01022" ref-type="bibr">17</xref>,<xref rid="B35-diagnostics-10-01022" ref-type="bibr">35</xref>], botulinum toxin type A for keloid [<xref rid="B38-diagnostics-10-01022" ref-type="bibr">38</xref>].</p><p>Furthermore, two specific surgery strategies were described: the stellate ganglion blockade for SFN causing burning mouth syndrome [<xref rid="B41-diagnostics-10-01022" ref-type="bibr">41</xref>] and the dorsal root ganglion stimulation for neuropathic pain of feet [<xref rid="B25-diagnostics-10-01022" ref-type="bibr">25</xref>]. </p><p>Motor exercises and a rehabilitative program could be part of the treatment strategy [<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>,<xref rid="B20-diagnostics-10-01022" ref-type="bibr">20</xref>,<xref rid="B21-diagnostics-10-01022" ref-type="bibr">21</xref>,<xref rid="B30-diagnostics-10-01022" ref-type="bibr">30</xref>,<xref rid="B36-diagnostics-10-01022" ref-type="bibr">36</xref>,<xref rid="B40-diagnostics-10-01022" ref-type="bibr">40</xref>,<xref rid="B42-diagnostics-10-01022" ref-type="bibr">42</xref>].</p></sec></sec><sec sec-type="discussion" id="sec4-diagnostics-10-01022"><title>4. Discussion</title><p>Our systematic review focused on the several pharmacological and rehabilitative therapies used for SFN. We realized a comprehensive overview to give a guide to ease the collaboration of a multidisciplinary team.</p><sec id="sec4dot1-diagnostics-10-01022"><title>4.1. Comparing Studies: Therapeutic Strategies</title><p>To choose the correct therapeutic approach, the first step is to confirm the diagnosis. Then it is essential to search for associated conditions because these could be treatable [<xref rid="B48-diagnostics-10-01022" ref-type="bibr">48</xref>]. </p><p>Several causes of SFN are potentially treatable [<xref rid="B49-diagnostics-10-01022" ref-type="bibr">49</xref>], such as metabolic syndrome [<xref rid="B50-diagnostics-10-01022" ref-type="bibr">50</xref>,<xref rid="B51-diagnostics-10-01022" ref-type="bibr">51</xref>], and type 2 diabetes [<xref rid="B52-diagnostics-10-01022" ref-type="bibr">52</xref>] associated with SFN. If the condition is not preventable, pharmacologic treatment and rehabilitation could improve the impairment and the quality of life. The treatment of symptoms is mandatory, and the possibility to add exercises and rehabilitation programs could permit to avoid disability and to maintain an adequate quality of life [<xref rid="B53-diagnostics-10-01022" ref-type="bibr">53</xref>].</p></sec><sec id="sec4dot2-diagnostics-10-01022"><title>4.2. The Pharmacological Approaches</title><p>The management of neuropathic pain has been a challenging task for physicians [<xref rid="B24-diagnostics-10-01022" ref-type="bibr">24</xref>]. There is limited evidence on the effectiveness of specific medications for the treatment of pain associated with SFN, and the most commonly used medications include antidepressants, anticonvulsants, mexiletine, topical agents, opiates and neuromodulation [<xref rid="B54-diagnostics-10-01022" ref-type="bibr">54</xref>,<xref rid="B55-diagnostics-10-01022" ref-type="bibr">55</xref>]. The guidelines for the pharmacologic management of neuropathic pain and diabetic painful polyneuropathies of the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS) [<xref rid="B56-diagnostics-10-01022" ref-type="bibr">56</xref>,<xref rid="B57-diagnostics-10-01022" ref-type="bibr">57</xref>] could be adopted for the treatment of SFN. The opioid analgesics may contribute to a centrally-sensitized pain state, which may be refractory to other symptomatic approaches [<xref rid="B58-diagnostics-10-01022" ref-type="bibr">58</xref>], with the activation of microglial cells [<xref rid="B58-diagnostics-10-01022" ref-type="bibr">58</xref>] and of the central glutaminergic system [<xref rid="B59-diagnostics-10-01022" ref-type="bibr">59</xref>]. About 45% of sarcoidosis-related SFN was treated with opioid analgesic therapy as the first approach [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>]. In the case report of Mishra et al. [<xref rid="B26-diagnostics-10-01022" ref-type="bibr">26</xref>], flupirtine, a nonopioid analgesic with muscle-relaxing properties, reduced neuropathic pain. Keohane et al. [<xref rid="B22-diagnostics-10-01022" ref-type="bibr">22</xref>] proposed tafamidis, a non-NSAID highly specific transthyretin stabilizer, to delay the neurologic disease progression in the early-stage of transthyretin V30M familial amyloid polyneuropathy. A neuropathic pain related to SFN secondary to a keloid was treated successfully with botulinum toxin type A [<xref rid="B38-diagnostics-10-01022" ref-type="bibr">38</xref>].</p><p>Immunotherapy with infliximab [<xref rid="B19-diagnostics-10-01022" ref-type="bibr">19</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>] or adalimumab [<xref rid="B14-diagnostics-10-01022" ref-type="bibr">14</xref>] could play a crucial role in modifying the pathogenesis of SFN in immune-mediated inflammatory diseases [<xref rid="B19-diagnostics-10-01022" ref-type="bibr">19</xref>]. </p><p>The use of corticosteroids, immunosuppressive and anti-epileptic drugs showed discordant results. No improvements were reported in neuropathic symptoms and pain intensity after corticosteroid treatment in Sjogren, sarcoidosis and Guillain&#x02013;Barr&#x000e9; related SFN [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>,<xref rid="B44-diagnostics-10-01022" ref-type="bibr">44</xref>], or marked clinical improvement, according to other studies [<xref rid="B10-diagnostics-10-01022" ref-type="bibr">10</xref>,<xref rid="B33-diagnostics-10-01022" ref-type="bibr">33</xref>,<xref rid="B34-diagnostics-10-01022" ref-type="bibr">34</xref>]. No clinical improvements were noted with methotrexate [<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>], but positive results with mycophenolate mofetil [<xref rid="B33-diagnostics-10-01022" ref-type="bibr">33</xref>]. Nevoret et al. [<xref rid="B29-diagnostics-10-01022" ref-type="bibr">29</xref>] added azathioprine to IVIG therapy, with consequent improvement in neuropathic symptomatology. </p><p>The benefits of intravenous immunoglobulin (IVIG) were reported for neuropathic pain in Sjogren [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>,<xref rid="B27-diagnostics-10-01022" ref-type="bibr">27</xref>]. In 8 studies, the efficacy and safety of IVIg are evaluated in patients with different features of SFN [<xref rid="B12-diagnostics-10-01022" ref-type="bibr">12</xref>,<xref rid="B15-diagnostics-10-01022" ref-type="bibr">15</xref>,<xref rid="B23-diagnostics-10-01022" ref-type="bibr">23</xref>,<xref rid="B27-diagnostics-10-01022" ref-type="bibr">27</xref>,<xref rid="B31-diagnostics-10-01022" ref-type="bibr">31</xref>,<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>,<xref rid="B39-diagnostics-10-01022" ref-type="bibr">39</xref>,<xref rid="B46-diagnostics-10-01022" ref-type="bibr">46</xref>,<xref rid="B47-diagnostics-10-01022" ref-type="bibr">47</xref>]. In contrast, IVIG had disappointing results, according to Pereira et al. [<xref rid="B33-diagnostics-10-01022" ref-type="bibr">33</xref>] and Yuki et al. [<xref rid="B44-diagnostics-10-01022" ref-type="bibr">44</xref>].</p><p>Gonzalez-Duarte et al. [<xref rid="B16-diagnostics-10-01022" ref-type="bibr">16</xref>] showed improvements in prediabetic neuropathic pain after pregabalin treatment. De Greef et al. [<xref rid="B11-diagnostics-10-01022" ref-type="bibr">11</xref>,<xref rid="B13-diagnostics-10-01022" ref-type="bibr">13</xref>], Namer et al. [<xref rid="B28-diagnostics-10-01022" ref-type="bibr">28</xref>] and Brouwer et al. [<xref rid="B60-diagnostics-10-01022" ref-type="bibr">60</xref>] assessed the efficacy, safety, and tolerability of lacosamide, an anticonvulsant, in patients with SCN-associated small fiber neuropathy. Carbamazepine is useful to reduce SFN-related neuropathy [<xref rid="B32-diagnostics-10-01022" ref-type="bibr">32</xref>] too. Gabapentin and naproxen [<xref rid="B4-diagnostics-10-01022" ref-type="bibr">4</xref>] or duloxetine [<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>] were used for SFN associated with hantavirus infection [<xref rid="B4-diagnostics-10-01022" ref-type="bibr">4</xref>] or in the absence of results with other therapies [<xref rid="B4-diagnostics-10-01022" ref-type="bibr">4</xref>].</p><p>Enzyme replacement therapy (ERT) with recombinant human &#x003b1;-galactosidase significantly improved the function of C-, A&#x00394;-, and A&#x000df;- nerve fibers and intradermal vibration receptors in Fabry neuropathy [<xref rid="B17-diagnostics-10-01022" ref-type="bibr">17</xref>]. But according to Schiffmann et al. [<xref rid="B35-diagnostics-10-01022" ref-type="bibr">35</xref>] epidermal nerve fiber regeneration did not occur after ERT. Van Velzen et al. [<xref rid="B45-diagnostics-10-01022" ref-type="bibr">45</xref>] described the long-lasting beneficial effects of ARA290, an erythropoietin derivate, in symptoms of sarcoidosis-related SFN in patients. According to Apfel et al. [<xref rid="B5-diagnostics-10-01022" ref-type="bibr">5</xref>], recombinant human nerve growth factors had significant beneficial effects on diabetic polyneuropathy. In the case report of Cao et al. [<xref rid="B9-diagnostics-10-01022" ref-type="bibr">9</xref>], SFN related to aquagenic pruritus was treated with propranolol with significative benefit after a month of therapy. Plasma exchange therapy is effective in patients with severe long-standing complex regional pain syndrome [<xref rid="B6-diagnostics-10-01022" ref-type="bibr">6</xref>].</p></sec><sec id="sec4dot3-diagnostics-10-01022"><title>4.3. Surgical Approaches</title><p>Stellate ganglion blockade [<xref rid="B41-diagnostics-10-01022" ref-type="bibr">41</xref>] for recalcitrant pain in burning mouth syndrome and dorsal root ganglion stimulation [<xref rid="B25-diagnostics-10-01022" ref-type="bibr">25</xref>] induced paraesthesia covering the entire pain area could be an effective therapy in SFN.</p></sec><sec id="sec4dot4-diagnostics-10-01022"><title>4.4. Rehabilitative Program</title><p>Another important field of therapy in SFN is the rehabilitation that could be added at a pharmacologic treatment [<xref rid="B21-diagnostics-10-01022" ref-type="bibr">21</xref>,<xref rid="B36-diagnostics-10-01022" ref-type="bibr">36</xref>] or used in the absence of pharmacologic results [<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>] and could be the first step of a therapy protocol (<xref rid="diagnostics-10-01022-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec4dot5-diagnostics-10-01022"><title>4.5. Implication in Rehabilitation</title><p>Early recognition of SFN is important to start an appropriate and prompt treatment.</p><p>The aim of therapy is to relieve the neuropathic symptoms. The reduction of pain and the improvement in quality of life and in the ability to participate in activities is the purpose of rehabilitation approaches and could be the best complementary treatment to pharmacologic strategies. Specific exercises with proprioceptive and superficial sensibility stimulation could enhance recovery. Exercise may positively influence the pathological factors associated with neuropathy by promoting microvascular dilation, reducing oxidative stress, and increasing neurotrophic factors [<xref rid="B61-diagnostics-10-01022" ref-type="bibr">61</xref>,<xref rid="B62-diagnostics-10-01022" ref-type="bibr">62</xref>].</p></sec></sec><sec id="sec5-diagnostics-10-01022"><title>5. Limitations</title><p>A lack of uniformity among the papers (measured parameters and assessment scale) may affect the outcomes of considered articles. The absence of information about some clinical characteristics that could influence the symptomatology represents another limitation, such as comorbidities, the use of other specific drugs, psychologic traits. Furthermore, in some articles, the sample was very small. Several studies did not assess participants&#x02019; educational status; it could be a confounding factor and could influence the results.</p></sec><sec sec-type="conclusions" id="sec6-diagnostics-10-01022"><title>6. Conclusions</title><p>The treatment of SFN is indispensable for the improvement of quality of life of individuals with neuropathic symptoms. SFN has a negative psychosocial impact on the lives of the patients and of their families.</p><p>We showed all the therapeutic approaches described in the current literature for SFN. On the basis of the different treatments, the physicians could obtain a guide and a common protocol for a multidisciplinary team. Despite the range of therapies for SFN, robust trials miss and always different therapeutic approaches are used. A comprehensive overview could give a guide to the physicians, and a complete protocol could ease the therapeutic and diagnostic approach to small fiber neuropathies. More research is needed to build evidence for the best therapy and to delineate a definitive therapeutic protocol.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>M.V., R.C., M.R., P.P., G.M., and G.L.M. conceived of the presented idea and verified the methods. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-diagnostics-10-01022"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkers</surname><given-names>M.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>Hoeijmakes</surname><given-names>J.G.J.</given-names></name><name><surname>Lauria</surname><given-names>G.</given-names></name><name><surname>Merkies</surname><given-names>I.S.J.</given-names></name></person-group><article-title>Small Fibers, Large Impact: Quality of Life in Small-Fiber Neuropathy</article-title><source>Muscle Nerve</source><year>2014</year><volume>49</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1002/mus.23910</pub-id><pub-id pub-id-type="pmid">23716362</pub-id></element-citation></ref><ref id="B2-diagnostics-10-01022"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamseer</surname><given-names>L.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Clarke</surname><given-names>M.</given-names></name><name><surname>Ghersi</surname><given-names>D.</given-names></name><name><surname>Liberati</surname><given-names>A.</given-names></name><name><surname>Petticrew</surname><given-names>M.</given-names></name><name><surname>Shekelle</surname><given-names>P.</given-names></name><name><surname>Stewart</surname><given-names>L.A.</given-names></name></person-group><article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation</article-title><source>BMJ</source><year>2015</year><volume>350</volume><fpage>7647</fpage><pub-id pub-id-type="doi">10.1136/bmj.g7647</pub-id></element-citation></ref><ref id="B3-diagnostics-10-01022"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>J.P.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>P.C.</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P.</given-names></name><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Oxman</surname><given-names>A.D.</given-names></name><name><surname>Savovi&#x00107;</surname><given-names>J.</given-names></name><name><surname>Schulz</surname><given-names>K.F.</given-names></name><name><surname>Weeks</surname><given-names>L.</given-names></name><name><surname>Sterne</surname><given-names>J.A.</given-names></name></person-group><article-title>The Cochrane Collaboration&#x02019;s tool for assessing risk of bias in randomised trials</article-title><source>Br. Med. J.</source><year>2011</year><volume>343</volume><fpage>889</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1136/bmj.d5928</pub-id></element-citation></ref><ref id="B4-diagnostics-10-01022"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D.</given-names></name><name><surname>Beecher</surname><given-names>G.</given-names></name><name><surname>Power</surname><given-names>C.</given-names></name><name><surname>Bridgland</surname><given-names>L.</given-names></name><name><surname>Zochodne</surname><given-names>D.W.</given-names></name></person-group><article-title>A Neuropathic Pain Syndrome Associated With Hantavirus Infection</article-title><source>J. Neurovirol.</source><year>2017</year><volume>23</volume><fpage>919</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1007/s13365-017-0576-2</pub-id><pub-id pub-id-type="pmid">28895058</pub-id></element-citation></ref><ref id="B5-diagnostics-10-01022"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apfel</surname><given-names>S.C.</given-names></name><name><surname>Schwartz</surname><given-names>S.</given-names></name><name><surname>Adornato</surname><given-names>B.T.</given-names></name><name><surname>Freeman</surname><given-names>R.</given-names></name><name><surname>Biton</surname><given-names>V.</given-names></name><name><surname>Rendell</surname><given-names>M.</given-names></name><name><surname>Vinik</surname><given-names>A.</given-names></name><name><surname>Giuliani</surname><given-names>M.</given-names></name><name><surname>Stevens</surname><given-names>J.C.</given-names></name><name><surname>Barbano</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial. rhNGF Clinical Investigator Group</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>2215</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1001/jama.284.17.2215</pub-id><pub-id pub-id-type="pmid">11056593</pub-id></element-citation></ref><ref id="B6-diagnostics-10-01022"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aradillas</surname><given-names>E.</given-names></name><name><surname>Schwartzman</surname><given-names>R.J.</given-names></name><name><surname>Grothusen</surname><given-names>J.R.</given-names></name><name><surname>Goebel</surname><given-names>A.</given-names></name><name><surname>Alexandder</surname><given-names>G.M.</given-names></name></person-group><article-title>Plasma Exchange Therapy in Patients with Complex Regional Pain Syndrome</article-title><source>Pain Physician</source><year>2015</year><volume>18</volume><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">26218942</pub-id></element-citation></ref><ref id="B7-diagnostics-10-01022"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azmi</surname><given-names>S.</given-names></name><name><surname>Ferdousi</surname><given-names>M.</given-names></name><name><surname>Petropoulos</surname><given-names>I.N.</given-names></name><name><surname>Ponirakis</surname><given-names>G.</given-names></name><name><surname>Fadavi</surname><given-names>H.</given-names></name><name><surname>Tavakoli</surname><given-names>M.</given-names></name><name><surname>Alam</surname><given-names>U.</given-names></name><name><surname>Jones</surname><given-names>W.</given-names></name><name><surname>Marshall</surname><given-names>A.</given-names></name><name><surname>Jeziorska</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Corneal Confocal Microscopy Shows an Improvement in Small-Fiber Neuropathy in Subjects With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Compared With Multiple Daily Injection</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>e3</fpage><lpage>e4</lpage><pub-id pub-id-type="doi">10.2337/dc14-1698</pub-id><pub-id pub-id-type="pmid">25538321</pub-id></element-citation></ref><ref id="B8-diagnostics-10-01022"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>J.</given-names></name><name><surname>Lalji</surname><given-names>A.</given-names></name><name><surname>Saed</surname><given-names>A.</given-names></name><name><surname>Baer</surname><given-names>A.N.</given-names></name></person-group><article-title>Biopsy-Proven Small-Fiber Neuropathy in Primary Sj&#x000f6;gren&#x02019;s Syndrome: Neuropathic Pain Characteristics, Autoantibody Findings, and Histopathologic Features</article-title><source>Arthritis Care Res.</source><year>2019</year><volume>71</volume><fpage>936</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1002/acr.23762</pub-id></element-citation></ref><ref id="B9-diagnostics-10-01022"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>T.</given-names></name><name><surname>Yong</surname><given-names>A.A.</given-names></name><name><surname>Tan</surname><given-names>K.B.</given-names></name><name><surname>Tey</surname><given-names>H.L.</given-names></name></person-group><article-title>Idiopathic Aquagenic Pruritus: Pathogenesis and Effective Treatment with Atenolol</article-title><source>Dermatol. Ther.</source><year>2015</year><volume>28</volume><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1111/dth.12194</pub-id><pub-id pub-id-type="pmid">25640024</pub-id></element-citation></ref><ref id="B10-diagnostics-10-01022"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabby</surname><given-names>R.</given-names></name><name><surname>Gilad</surname><given-names>R.</given-names></name><name><surname>Sadeh</surname><given-names>M.</given-names></name><name><surname>Lampl</surname><given-names>Y.</given-names></name><name><surname>Water&#x000ec;mberg</surname><given-names>N.</given-names></name></person-group><article-title>Acute steroid responsive small-fiber sensory neuropathy: A new entity</article-title><source>J. Peripher. Nerv. Syst.</source><year>2006</year><volume>11</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/j.1085-9489.2006.00062.x</pub-id><pub-id pub-id-type="pmid">16519781</pub-id></element-citation></ref><ref id="B11-diagnostics-10-01022"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Greef</surname><given-names>B.</given-names></name><name><surname>Merkies</surname><given-names>I.S.J.</given-names></name><name><surname>Geerts</surname><given-names>M.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>Hoeijmakers</surname><given-names>J.G.J.</given-names></name></person-group><article-title>Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: Study protocol of a randomized controlled trial-the LENSS study</article-title><source>Trials</source><year>2016</year><volume>17</volume><pub-id pub-id-type="doi">10.1186/s13063-016-1430-1</pub-id></element-citation></ref><ref id="B12-diagnostics-10-01022"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Greef</surname><given-names>B.T.</given-names></name><name><surname>Geerts</surname><given-names>M.</given-names></name><name><surname>Hoeijmakers</surname><given-names>J.G.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>Merkies</surname><given-names>S.J.</given-names></name></person-group><article-title>Intravenous immunoglobulin therapy for small fiber neuropathy: Study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2016</year><volume>17</volume><fpage>330</fpage><pub-id pub-id-type="doi">10.1186/s13063-016-1450-x</pub-id><pub-id pub-id-type="pmid">27439408</pub-id></element-citation></ref><ref id="B13-diagnostics-10-01022"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Greef</surname><given-names>B.T.</given-names></name><name><surname>Hoeijmakers</surname><given-names>J.G.</given-names></name><name><surname>Geerts</surname><given-names>M.</given-names></name><name><surname>Oakes</surname><given-names>M.</given-names></name><name><surname>Church</surname><given-names>T.J.</given-names></name><name><surname>Waxman</surname><given-names>S.G.</given-names></name><name><surname>Dib-Hajj</surname><given-names>S.D.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>Merkies</surname><given-names>I.S.</given-names></name></person-group><article-title>Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: A randomized controlled trial</article-title><source>Brain</source><year>2019</year><volume>142</volume><fpage>263</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1093/brain/awy329</pub-id><pub-id pub-id-type="pmid">30649227</pub-id></element-citation></ref><ref id="B14-diagnostics-10-01022"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favon</surname><given-names>V.</given-names></name><name><surname>Liguoi</surname><given-names>R.</given-names></name><name><surname>Incensi</surname><given-names>A.</given-names></name><name><surname>Fileccia</surname><given-names>E.</given-names></name><name><surname>Donadio</surname><given-names>V.</given-names></name></person-group><article-title>The Incidental Finding of Elevated Anti GQ1B Antibodies in a Patient With Selective Small Fiber Neuropathy</article-title><source>J. Neurol. Sci.</source><year>2018</year><volume>388</volume><fpage>192</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2018.03.030</pub-id><pub-id pub-id-type="pmid">29627021</pub-id></element-citation></ref><ref id="B15-diagnostics-10-01022"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaillet</surname><given-names>A.</given-names></name><name><surname>Champion</surname><given-names>K.</given-names></name><name><surname>Lefaucheur</surname><given-names>J.P.</given-names></name><name><surname>Trout</surname><given-names>H.</given-names></name><name><surname>Bergmann</surname><given-names>J.F.</given-names></name><name><surname>Sene</surname><given-names>D.</given-names></name></person-group><article-title>Intravenous Immunoglobulin Efficacy for Primary Sj&#x000f6;gren&#x02019;s Syndrome Associated Small Fiber Neuropathy</article-title><source>Autoimmun. Rev.</source><year>2019</year><volume>18</volume><fpage>102387</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2019.102387</pub-id><pub-id pub-id-type="pmid">31520801</pub-id></element-citation></ref><ref id="B16-diagnostics-10-01022"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Duarte</surname><given-names>A.</given-names></name><name><surname>Lem</surname><given-names>M.</given-names></name><name><surname>D&#x000ed;az-D&#x000ed;az</surname><given-names>E.</given-names></name><name><surname>Castillo</surname><given-names>C.</given-names></name><name><surname>C&#x000e1;rdenas-Soto</surname><given-names>K.</given-names></name></person-group><article-title>The Efficacy of Pregabalin in the Treatment of Prediabetic Neuropathic Pain</article-title><source>Clin. J. Pain</source><year>2016</year><volume>32</volume><fpage>927</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1097/AJP.0000000000000339</pub-id><pub-id pub-id-type="pmid">26670614</pub-id></element-citation></ref><ref id="B17-diagnostics-10-01022"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilz</surname><given-names>M.J.</given-names></name><name><surname>Brys</surname><given-names>M.</given-names></name><name><surname>Marthol</surname><given-names>H.</given-names></name><name><surname>Stemper</surname><given-names>B.</given-names></name><name><surname>Dutsc</surname><given-names>M.</given-names></name></person-group><article-title>Enzyme Replacement Therapy for Fabry Disease</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>1066</fpage><lpage>1072</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000118207.84514.40</pub-id><pub-id pub-id-type="pmid">15079003</pub-id></element-citation></ref><ref id="B18-diagnostics-10-01022"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeijmakers</surname><given-names>J.G.J.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>Miedema</surname><given-names>C.J.</given-names></name><name><surname>Merkies</surname><given-names>I.S.J.</given-names></name><name><surname>Vles</surname><given-names>J.S.H.</given-names></name></person-group><article-title>Small Fiber Neuropathy in Children: Two Case Reports Illustrating the Importance of Recognition</article-title><source>Pediatrics</source><year>2016</year><volume>138</volume><fpage>e20161215</fpage><pub-id pub-id-type="doi">10.1542/peds.2016-1215</pub-id><pub-id pub-id-type="pmid">27660061</pub-id></element-citation></ref><ref id="B19-diagnostics-10-01022"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoitsma</surname><given-names>E.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name><name><surname>van Santen-Hoeufft</surname><given-names>M.</given-names></name><name><surname>De Vries</surname><given-names>J.</given-names></name><name><surname>Reulen</surname><given-names>J.P.H.</given-names></name><name><surname>Drent</surname><given-names>M.</given-names></name></person-group><article-title>Improvement of small fiber neuropathy in a sarcoidosis patient after treatment</article-title><source>Sarcoidosis Vasc. Diffuse Lung Dis.</source><year>2006</year><volume>23</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16933474</pub-id></element-citation></ref><ref id="B20-diagnostics-10-01022"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Barnes</surname><given-names>M.</given-names></name><name><surname>Kessler</surname><given-names>N.</given-names></name></person-group><article-title>Case study: Use of vibration therapy in the treatment of diabetic peripheral small fiber neuropathy</article-title><source>J. Bodyw. Mov. Ther.</source><year>2013</year><volume>17</volume><fpage>235</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1016/j.jbmt.2012.08.007</pub-id><pub-id pub-id-type="pmid">23561872</pub-id></element-citation></ref><ref id="B21-diagnostics-10-01022"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluding</surname><given-names>P.M.</given-names></name><name><surname>Pasnoor</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Jernigan</surname><given-names>S.</given-names></name><name><surname>Farmer</surname><given-names>K.</given-names></name><name><surname>Rucker</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>N.K.</given-names></name><name><surname>Wright</surname><given-names>D.E.</given-names></name></person-group><article-title>The Effect of Exercise on Neuropathic Symptoms, Nerve Function, and Cutaneous Innervation in People With Diabetic Peripheral Neuropathy</article-title><source>J. Diabetes Complicat.</source><year>2012</year><volume>26</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2012.05.007</pub-id></element-citation></ref><ref id="B22-diagnostics-10-01022"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keohane</surname><given-names>D.</given-names></name><name><surname>Scwartz</surname><given-names>J.</given-names></name><name><surname>Gundapaneni</surname><given-names>B.</given-names></name><name><surname>Stewart</surname><given-names>M.</given-names></name><name><surname>Amass</surname><given-names>L.</given-names></name></person-group><article-title>Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: Additional supportive analyses from the pivotal trial</article-title><source>Amyloid</source><year>2017</year><volume>24</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1080/13506129.2017.1301419</pub-id></element-citation></ref><ref id="B23-diagnostics-10-01022"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Treister</surname><given-names>R.</given-names></name><name><surname>Lang</surname><given-names>M.</given-names></name><name><surname>Oaklander</surname><given-names>A.L.</given-names></name></person-group><article-title>IVIg for Apparently Autoimmune Small-Fiber Polyneuropathy: First Analysis of Efficacy and Safety</article-title><source>Ther. Adv. Neurol. Disord.</source><year>2018</year><volume>11</volume><fpage>1756285617744484</fpage><pub-id pub-id-type="doi">10.1177/1756285617744484</pub-id><pub-id pub-id-type="pmid">29403541</pub-id></element-citation></ref><ref id="B24-diagnostics-10-01022"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>T.L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Polston</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Longitudinal Follow-Up of Biopsy-Proven Small Fiber Neuropathy</article-title><source>Muscle Nerve</source><year>2019</year><volume>60</volume><fpage>376</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1002/mus.26648</pub-id><pub-id pub-id-type="pmid">31348533</pub-id></element-citation></ref><ref id="B25-diagnostics-10-01022"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maino</surname><given-names>P.</given-names></name><name><surname>Koetsier</surname><given-names>E.</given-names></name><name><surname>Kaelin-Lamg</surname><given-names>A.</given-names></name><name><surname>Gobbi</surname><given-names>C.</given-names></name><name><surname>Perez</surname><given-names>R.</given-names></name></person-group><article-title>Efficacious Dorsal Root Ganglion Stimulation for Painful Small Fiber Neuropathy: A Case Report</article-title><source>Pain Physician</source><year>2017</year><volume>20</volume><fpage>E459</fpage><lpage>E463</lpage><pub-id pub-id-type="pmid">28339448</pub-id></element-citation></ref><ref id="B26-diagnostics-10-01022"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S.</given-names></name><name><surname>Choudhary</surname><given-names>P.</given-names></name><name><surname>Joshi</surname><given-names>S.</given-names></name><name><surname>Bhatnagar</surname><given-names>S.</given-names></name></person-group><article-title>Successful Use of Flupirtine in Refractory Neuropathic Pain Due to Small Fiber Neuropathy</article-title><source>Am. J. Hosp. Palliat. Care</source><year>2013</year><volume>30</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/1049909112441387</pub-id><pub-id pub-id-type="pmid">22495792</pub-id></element-citation></ref><ref id="B27-diagnostics-10-01022"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morozumi</surname><given-names>S.</given-names></name><name><surname>Kawagashira</surname><given-names>Y.</given-names></name><name><surname>Lijima</surname><given-names>M.</given-names></name><name><surname>Koike</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Katsuno</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>F.</given-names></name><name><surname>Sobue</surname><given-names>G.</given-names></name></person-group><article-title>Intravenous Immunoglobulin Treatment for Painful Sensory Neuropathy Associated With Sj&#x000f6;gren&#x02019;s Syndrome</article-title><source>J. Neurol. Sci.</source><year>2009</year><volume>279</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2008.12.018</pub-id><pub-id pub-id-type="pmid">19168191</pub-id></element-citation></ref><ref id="B28-diagnostics-10-01022"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namer</surname><given-names>B.</given-names></name><name><surname>Schmidt</surname><given-names>D.</given-names></name><name><surname>Eberhardt</surname><given-names>E.</given-names></name><name><surname>Maroni</surname><given-names>M.</given-names></name><name><surname>Dorfmeister</surname><given-names>E.</given-names></name><name><surname>Kleggetveit</surname><given-names>I.P.</given-names></name><name><surname>Kaluza</surname><given-names>L.</given-names></name><name><surname>Meents</surname><given-names>J.</given-names></name><name><surname>Gerlach</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Pain Relief in a Neuropathy Patient by Lacosamide: Proof of Principle of Clinical Translation From Patient-Specific iPS Cell-Derived Nociceptors</article-title><source>EBioMedicine</source><year>2019</year><volume>39</volume><fpage>401</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.042</pub-id><pub-id pub-id-type="pmid">30503201</pub-id></element-citation></ref><ref id="B29-diagnostics-10-01022"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nevoret</surname><given-names>M.</given-names></name><name><surname>Vinik</surname><given-names>A.I.</given-names></name></person-group><article-title>CIDP Variants in Diabetes: Measuring Treatment Response with a Small Nerve Fiber Test</article-title><source>J. Diabetes Complicat.</source><year>2015</year><volume>29</volume><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.jdiacomp.2014.10.012</pub-id></element-citation></ref><ref id="B30-diagnostics-10-01022"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otis</surname><given-names>J.D.</given-names></name><name><surname>Sanderson</surname><given-names>K.</given-names></name><name><surname>Hardway</surname><given-names>C.</given-names></name><name><surname>Pincus</surname><given-names>M.</given-names></name><name><surname>Soumekh</surname><given-names>S.</given-names></name></person-group><article-title>A Randomized Controlled Pilot Study of a Cognitive-Behavioral therapy approach for painful diabetic peripheral neuropathy</article-title><source>J. Pain</source><year>2013</year><volume>14</volume><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2012.12.013</pub-id><pub-id pub-id-type="pmid">23452825</pub-id></element-citation></ref><ref id="B31-diagnostics-10-01022"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parambil</surname><given-names>J.G.</given-names></name><name><surname>Tavee</surname><given-names>J.O.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Pearson</surname><given-names>K.S.</given-names></name><name><surname>Culver</surname><given-names>D.A.</given-names></name></person-group><article-title>Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis</article-title><source>Respir. Med.</source><year>2011</year><volume>105</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2010.09.015</pub-id><pub-id pub-id-type="pmid">20926271</pub-id></element-citation></ref><ref id="B32-diagnostics-10-01022"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Unikel</surname><given-names>L.H.</given-names></name><name><surname>Edwards</surname><given-names>C.</given-names></name></person-group><article-title>A case of sporadic erythromelalgia presenting with small fibre neuropathy</article-title><source>BMJ Case Rep.</source><year>2019</year><volume>12</volume><fpage>e230549</fpage><pub-id pub-id-type="doi">10.1136/bcr-2019-230549</pub-id></element-citation></ref><ref id="B33-diagnostics-10-01022"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>P.R.</given-names></name><name><surname>Viala</surname><given-names>K.</given-names></name><name><surname>Maisonobe</surname><given-names>T.</given-names></name><name><surname>Haroche</surname><given-names>J.</given-names></name><name><surname>Mathian</surname><given-names>A.</given-names></name><name><surname>Hi&#x000e8;</surname><given-names>M.</given-names></name><name><surname>Amoura</surname><given-names>Z.</given-names></name><name><surname>Aubart</surname><given-names>F.C.</given-names></name></person-group><article-title>Sj&#x000f6;gren Sensory Neuronopathy (Sj&#x000f6;gren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases</article-title><source>Medicine</source><year>2016</year><volume>95</volume><fpage>e3632</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000003632</pub-id><pub-id pub-id-type="pmid">27175675</pub-id></element-citation></ref><ref id="B34-diagnostics-10-01022"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>H.</given-names></name><name><surname>Yamaguchi</surname><given-names>T.</given-names></name><name><surname>Adachi</surname><given-names>Y.</given-names></name><name><surname>Yamashita</surname><given-names>T.</given-names></name><name><surname>Wakai</surname><given-names>Y.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Shinora</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>K.</given-names></name><name><surname>Yagihasshi</surname><given-names>S.</given-names></name><name><surname>Terada</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Neurological Symptoms of Sarcoidosis-induced Small Fiber Neuropathy Effectively Relieved With High-dose Steroid Pulse Therapy</article-title><source>Intern. Med.</source><year>2015</year><volume>54</volume><fpage>1281</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.54.3702</pub-id><pub-id pub-id-type="pmid">25986271</pub-id></element-citation></ref><ref id="B35-diagnostics-10-01022"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffann</surname><given-names>R.</given-names></name><name><surname>Hauer</surname><given-names>P.</given-names></name><name><surname>Freeman</surname><given-names>B.</given-names></name><name><surname>Ries</surname><given-names>M.</given-names></name><name><surname>Scott</surname><given-names>L.J.</given-names></name><name><surname>Polydefkis</surname><given-names>M.</given-names></name><name><surname>Brady</surname><given-names>R.O.</given-names></name><name><surname>McArthur</surname><given-names>J.C.</given-names></name><name><surname>Wagner</surname><given-names>K.</given-names></name></person-group><article-title>Enzyme Replacement Therapy and Intraepidermal Innervation Density in Fabry Disease</article-title><source>Muscle Nerve</source><year>2006</year><volume>34</volume><fpage>53</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/mus.20550</pub-id><pub-id pub-id-type="pmid">16583374</pub-id></element-citation></ref><ref id="B36-diagnostics-10-01022"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>G.</given-names></name><name><surname>Russell</surname><given-names>J.</given-names></name><name><surname>Feldman</surname><given-names>E.L.</given-names></name><name><surname>Goldstein</surname><given-names>J.</given-names></name><name><surname>Peltier</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name><name><surname>Hamwi</surname><given-names>J.</given-names></name><name><surname>Pollari</surname><given-names>D.</given-names></name><name><surname>Bixby</surname><given-names>B.</given-names></name><name><surname>Howard</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Lifestyle Intervention for Pre-Diabetic Neuropathy</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1294</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.2337/dc06-0224</pub-id><pub-id pub-id-type="pmid">16732011</pub-id></element-citation></ref><ref id="B37-diagnostics-10-01022"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavee</surname><given-names>J.O.</given-names></name><name><surname>Karwa</surname><given-names>K.</given-names></name><name><surname>AAhmed</surname><given-names>Z.</given-names></name><name><surname>Thompson</surname><given-names>N.</given-names></name><name><surname>Parambil</surname><given-names>J.</given-names></name><name><surname>Culver</surname><given-names>D.A.</given-names></name></person-group><article-title>Sarcoidosis-associated Small Fiber Neuropathy in a Large Cohort: Clinical Aspects and Response to IVIG and anti-TNF Alpha Treatment</article-title><source>Respir. Med.</source><year>2017</year><volume>126</volume><fpage>135</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2017.03.011</pub-id><pub-id pub-id-type="pmid">28318820</pub-id></element-citation></ref><ref id="B38-diagnostics-10-01022"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyesugi</surname><given-names>B.</given-names></name><name><surname>Lippincott</surname><given-names>B.</given-names></name><name><surname>Dave</surname><given-names>S.</given-names></name></person-group><article-title>Treatment of a Painful Keloid With Botulinum Toxin Type, A</article-title><source>Am. J. Phys. Med. Rehabil.</source><year>2010</year><volume>89</volume><fpage>153</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1097/PHM.0b013e3181c1ec11</pub-id><pub-id pub-id-type="pmid">19884811</pub-id></element-citation></ref><ref id="B39-diagnostics-10-01022"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakasugi</surname><given-names>D.</given-names></name><name><surname>Kato</surname><given-names>T.</given-names></name><name><surname>Gono</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>E.</given-names></name><name><surname>Nodera</surname><given-names>H.</given-names></name><name><surname>Kawaguchi</surname><given-names>Y.</given-names></name><name><surname>Yamanaka</surname><given-names>H.</given-names></name><name><surname>Hara</surname><given-names>M.</given-names></name></person-group><article-title>Extreme Efficacy of Intravenous Immunoglobulin Therapy for Severe Burning Pain in a Patient With Small Fiber Neuropathy Associated With Primary Sj&#x000f6;gren&#x02019;s Syndrome</article-title><source>Mod. Rheumatol.</source><year>2009</year><volume>19</volume><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.3109/s10165-009-0180-2</pub-id><pub-id pub-id-type="pmid">19458906</pub-id></element-citation></ref><ref id="B40-diagnostics-10-01022"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldinger</surname><given-names>M.D.</given-names></name><name><surname>Venema</surname><given-names>P.L.</given-names></name><name><surname>van Gils</surname><given-names>A.P.</given-names></name><name><surname>de Lint</surname><given-names>G.J.</given-names></name><name><surname>Schweitzer</surname><given-names>D.H.</given-names></name></person-group><article-title>Stronger evidence for small fiber sensory neuropathy in restless genital syndrome: Two case reports in males</article-title><source>J. Sex. Med.</source><year>2011</year><volume>8</volume><fpage>325</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1111/j.1743-6109.2010.02079.x</pub-id><pub-id pub-id-type="pmid">20955316</pub-id></element-citation></ref><ref id="B41-diagnostics-10-01022"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walega</surname><given-names>D.R.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Epstein</surname><given-names>J.B.</given-names></name></person-group><article-title>Oral Pain From Burning Mouth Syndrome: A Case Report</article-title><source>J. Oral Facial Pain Headache Spring</source><year>2014</year><volume>28</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.11607/ofph.1165</pub-id></element-citation></ref><ref id="B42-diagnostics-10-01022"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>M.I.</given-names></name><name><surname>Herrmann</surname><given-names>D.N.</given-names></name><name><surname>Smith</surname><given-names>A.G.</given-names></name><name><surname>Backonja</surname><given-names>M.M.</given-names></name><name><surname>Cole</surname><given-names>S.P.</given-names></name></person-group><article-title>Pulsed Electromagnetic Fields to Reduce Diabetic Neuropathic Pain and Stimulate Neuronal Repair: A Randomized Controlled Trial</article-title><source>Arch. Phys. Med. Rehabil.</source><year>2009</year><volume>90</volume><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2009.01.019</pub-id><pub-id pub-id-type="pmid">19577022</pub-id></element-citation></ref><ref id="B43-diagnostics-10-01022"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windebank</surname><given-names>A.J.</given-names></name><name><surname>Sorenson</surname><given-names>E.J.</given-names></name><name><surname>Civil</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>P.C.</given-names></name></person-group><article-title>Role of Insulin-Like Growth factor-I in the Treatment of Painful Small Fiber Predominant Neuropathy</article-title><source>J. Peripher. Nerv. Syst.</source><year>2004</year><volume>9</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1111/j.1085-9489.2004.09311.x</pub-id><pub-id pub-id-type="pmid">15363067</pub-id></element-citation></ref><ref id="B44-diagnostics-10-01022"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>N.</given-names></name><name><surname>Chan</surname><given-names>A.C.</given-names></name><name><surname>Wong</surname><given-names>A.H.Y.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Yokai</surname><given-names>M.</given-names></name><name><surname>Kurihara</surname><given-names>T.</given-names></name><name><surname>Devaux</surname><given-names>J.J.</given-names></name><name><surname>Wider-Smith</surname><given-names>E.</given-names></name></person-group><article-title>Acute Painful Autoimmune Neuropathy: A Variant of Guillain-Barr&#x000e9; Syndrome</article-title><source>Muscle Nerve</source><year>2018</year><volume>57</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/mus.25738</pub-id><pub-id pub-id-type="pmid">28667708</pub-id></element-citation></ref><ref id="B45-diagnostics-10-01022"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Velzen</surname><given-names>M.</given-names></name><name><surname>Heij</surname><given-names>L.</given-names></name><name><surname>Niesters</surname><given-names>M.</given-names></name><name><surname>Cerami</surname><given-names>A.</given-names></name><name><surname>Dunne</surname><given-names>A.</given-names></name><name><surname>Dahan</surname><given-names>A.</given-names></name><name><surname>Brines</surname><given-names>M.</given-names></name></person-group><article-title>ARA 290 for Treatment of Small Fiber Neuropathy in Sarcoidosis</article-title><source>Expert Opin. Investig. Drugs</source><year>2014</year><volume>23</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1517/13543784.2014.892072</pub-id></element-citation></ref><ref id="B46-diagnostics-10-01022"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oaklander</surname><given-names>A.L.</given-names></name></person-group><article-title>Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies</article-title><source>Neurotherapeutics</source><year>2016</year><volume>13</volume><fpage>108</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0395-1</pub-id><pub-id pub-id-type="pmid">26526686</pub-id></element-citation></ref><ref id="B47-diagnostics-10-01022"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kizawa</surname><given-names>M.</given-names></name><name><surname>Mori</surname><given-names>K.</given-names></name><name><surname>Iijima</surname><given-names>M.</given-names></name><name><surname>Koike</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Sobue</surname><given-names>G.</given-names></name></person-group><article-title>Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sj&#x000f6;gren&#x02019;s syndrome</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2006</year><volume>77</volume><fpage>967</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2005.084533</pub-id><pub-id pub-id-type="pmid">16844955</pub-id></element-citation></ref><ref id="B48-diagnostics-10-01022"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaramonte</surname><given-names>R.</given-names></name><name><surname>Romano</surname><given-names>M.</given-names></name><name><surname>Vecchio</surname><given-names>M.</given-names></name></person-group><article-title>A Systematic Review of the Diagnostic Methods of Small Fiber Neuropathies in Rehabilitation</article-title><source>Diagnostics</source><year>2020</year><volume>10</volume><elocation-id>613</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics10090613</pub-id></element-citation></ref><ref id="B49-diagnostics-10-01022"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Themistocleous</surname><given-names>A.C.</given-names></name><name><surname>Ramirez</surname><given-names>J.D.</given-names></name><name><surname>Serra</surname><given-names>J.</given-names></name><name><surname>Bennett</surname><given-names>D.L.H.</given-names></name></person-group><article-title>The Clinical Approach to Small Fibre Neuropathy and Painful Channelopathy</article-title><source>Pract. Neurol.</source><year>2014</year><volume>14</volume><fpage>368</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1136/practneurol-2013-000758</pub-id><pub-id pub-id-type="pmid">24778270</pub-id></element-citation></ref><ref id="B50-diagnostics-10-01022"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Ontaneda</surname><given-names>D.</given-names></name><name><surname>Sperling</surname><given-names>J.</given-names></name></person-group><article-title>Metabolic Syndrome in Small Fiber Sensory Neuropathy</article-title><source>J. Clin. Neuromuscul. Dis.</source><year>2011</year><volume>12</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1097/CND.0b013e3182196e3c</pub-id><pub-id pub-id-type="pmid">22361523</pub-id></element-citation></ref><ref id="B51-diagnostics-10-01022"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerburg</surname><given-names>V.</given-names></name><name><surname>Bakkers</surname><given-names>M.</given-names></name><name><surname>Bouwhuis</surname><given-names>A.</given-names></name><name><surname>Hoeijmakers</surname><given-names>J.G.J.</given-names></name><name><surname>Smit</surname><given-names>M.</given-names></name><name><surname>Van Den Berg</surname><given-names>S.J.M.</given-names></name><name><surname>Hordijk-De Boer</surname><given-names>I.</given-names></name><name><surname>Brouwer-Van Der Lee</surname><given-names>M.D.G.</given-names></name><name><surname>Kranendonk</surname><given-names>D.</given-names></name><name><surname>Reulen</surname><given-names>J.P.H.</given-names></name><etal/></person-group><article-title>Contact Heat Evoked Potentials: Normal Values and Use in Small-Fiber Neuropathy</article-title><source>Muscle Nerve</source><year>2015</year><volume>51</volume><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1002/mus.24465</pub-id><pub-id pub-id-type="pmid">25256002</pub-id></element-citation></ref><ref id="B52-diagnostics-10-01022"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaghan</surname><given-names>B.C.</given-names></name><name><surname>Little</surname><given-names>A.A.</given-names></name><name><surname>Feldman</surname><given-names>E.L.</given-names></name><name><surname>Hughes</surname><given-names>R.A.C.</given-names></name></person-group><article-title>Enhanced Glucose Control for Preventing and Treating Diabetic Neuropathy</article-title><source>Cochrane Database Syst. Rev.</source><year>2012</year><volume>6</volume><fpage>CD007543</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD007543.pub2</pub-id></element-citation></ref><ref id="B53-diagnostics-10-01022"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castelnuovo</surname><given-names>G.</given-names></name><name><surname>Giusti</surname><given-names>E.M.</given-names></name><name><surname>Manzoni</surname><given-names>G.M.</given-names></name><name><surname>Saviola</surname><given-names>D.</given-names></name><name><surname>Gatti</surname><given-names>A.</given-names></name><name><surname>Gabrielli</surname><given-names>S.</given-names></name><name><surname>Lacerenza</surname><given-names>M.</given-names></name><name><surname>Pietrabissa</surname><given-names>G.</given-names></name><name><surname>Cattivelli</surname><given-names>R.</given-names></name><name><surname>Spatola</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Psychological Treatments and Psychotherapies in the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation</article-title><source>Front. Psychol.</source><year>2016</year><volume>7</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2016.00115</pub-id><pub-id pub-id-type="pmid">26924998</pub-id></element-citation></ref><ref id="B54-diagnostics-10-01022"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>A.C.Y.</given-names></name><name><surname>Wilder-Smith</surname><given-names>E.P.W.</given-names></name></person-group><article-title>Small Fiber Neuropathy: Getting Bigger!</article-title><source>Muscle Nerve</source><year>2016</year><volume>53</volume><fpage>671</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1002/mus.25082</pub-id><pub-id pub-id-type="pmid">26872938</pub-id></element-citation></ref><ref id="B55-diagnostics-10-01022"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavee</surname><given-names>J.O.</given-names></name></person-group><article-title>Office Approach to Small Fiber Neuropathy</article-title><source>Cleve Clin. J. Med.</source><year>2018</year><volume>85</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.3949/ccjm.85a.17124</pub-id><pub-id pub-id-type="pmid">30289758</pub-id></element-citation></ref><ref id="B56-diagnostics-10-01022"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attal</surname><given-names>N.</given-names></name><name><surname>Cruccu</surname><given-names>G.</given-names></name><name><surname>Baron</surname><given-names>R.</given-names></name><name><surname>Haanpaa</surname><given-names>M.</given-names></name><name><surname>Hanssom</surname><given-names>P.</given-names></name><name><surname>Jensen</surname><given-names>T.S.</given-names></name><name><surname>Nurmikko</surname><given-names>T.</given-names></name></person-group><article-title>EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision</article-title><source>Eur. J. Neurol.</source><year>2010</year><volume>17</volume><fpage>1113-e88</fpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.02999.x</pub-id><pub-id pub-id-type="pmid">20402746</pub-id></element-citation></ref><ref id="B57-diagnostics-10-01022"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bril</surname><given-names>V.</given-names></name><name><surname>England</surname><given-names>J.</given-names></name><name><surname>Franklin</surname><given-names>G.M.</given-names></name><name><surname>Backonja</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>J.</given-names></name><name><surname>Del Toro</surname><given-names>D.</given-names></name><name><surname>Feldman</surname><given-names>R.</given-names></name></person-group><article-title>Evidence-based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation</article-title><source>Neurology</source><year>2011</year><volume>76</volume><fpage>1758</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182166ebe</pub-id><pub-id pub-id-type="pmid">21482920</pub-id></element-citation></ref><ref id="B58-diagnostics-10-01022"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>R.J.</given-names></name><name><surname>Jung</surname><given-names>H.</given-names></name><name><surname>Bhangoo</surname><given-names>S.K.</given-names></name><name><surname>White</surname><given-names>F.A.</given-names></name></person-group><article-title>Cytokine and Chemokine Regulation of Sensory Neuron Function</article-title><source>Handb. Exp. Pharmacol.</source><year>2009</year><fpage>417</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/978-3-540-79090-7_12</pub-id><pub-id pub-id-type="pmid">19655114</pub-id></element-citation></ref><ref id="B59-diagnostics-10-01022"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J.</given-names></name><name><surname>Price</surname><given-names>D.D.</given-names></name><name><surname>Mayer</surname><given-names>D.J.</given-names></name></person-group><article-title>Mechanisms of Hyperalgesia and Morphine Tolerance: A Current View of Their Possible Interactions</article-title><source>Pain</source><year>1995</year><volume>62</volume><fpage>259</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(95)00073-2</pub-id><pub-id pub-id-type="pmid">8657426</pub-id></element-citation></ref><ref id="B60-diagnostics-10-01022"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>B.</given-names></name><name><surname>Merkies</surname><given-names>I.J.</given-names></name><name><surname>Gerrits</surname><given-names>M.M.</given-names></name><name><surname>Waxman</surname><given-names>S.G.</given-names></name><name><surname>Hoejmakers</surname><given-names>J.G.J.</given-names></name><name><surname>Faber</surname><given-names>C.G.</given-names></name></person-group><article-title>Painful Neuropathies: The Emerging Role of Sodium Channelopathies</article-title><source>J. Peripher. Nerv. Syst.</source><year>2014</year><volume>19</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/jns5.12071</pub-id><pub-id pub-id-type="pmid">25250524</pub-id></element-citation></ref><ref id="B61-diagnostics-10-01022"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadoglou</surname><given-names>N.P.E.</given-names></name><name><surname>Iliadis</surname><given-names>F.</given-names></name><name><surname>Angelopoulou</surname><given-names>N.</given-names></name><name><surname>Perrea</surname><given-names>D.</given-names></name><name><surname>Ampatzidis</surname><given-names>G.</given-names></name><name><surname>Liapis</surname><given-names>C.D.</given-names></name><name><surname>Alevizos</surname><given-names>M.</given-names></name></person-group><article-title>The Anti-Inflammatory Effects of Exercise Training in Patients with Type 2 Diabetes Mellitus</article-title><source>Eur. J. Cardiovasc. Prev. Rehabil.</source><year>2007</year><volume>14</volume><fpage>837</fpage><lpage>843</lpage><pub-id pub-id-type="doi">10.1097/HJR.0b013e3282efaf50</pub-id><pub-id pub-id-type="pmid">18043308</pub-id></element-citation></ref><ref id="B62-diagnostics-10-01022"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiorana</surname><given-names>A.</given-names></name><name><surname>O&#x02019;Driscoll</surname><given-names>G.</given-names></name><name><surname>Cheetham</surname><given-names>C.</given-names></name><name><surname>Dembo</surname><given-names>L.</given-names></name><name><surname>Stanton</surname><given-names>K.</given-names></name><name><surname>Goodman</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>R.</given-names></name><name><surname>Green</surname><given-names>D.</given-names></name></person-group><article-title>The Effect of Combined Aerobic and Resistance Exercise Training on Vascular Function in Type 2 Diabetes</article-title><source>J. Am. Coll. Cardiol.</source><year>2001</year><volume>38</volume><fpage>860</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01439-5</pub-id><pub-id pub-id-type="pmid">11527646</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="diagnostics-10-01022-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flowchart of the process of literature search and extraction of studies meeting the inclusion criteria.</p></caption><graphic xlink:href="diagnostics-10-01022-g001"/></fig><table-wrap id="diagnostics-10-01022-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-01022-t001_Table 1</object-id><label>Table 1</label><caption><p>Treatment of SFN. Characteristics and outcomes of studies included in the systematic review.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors, Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients. Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SFN Disease.<break/>Age at Onset Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Onset SFN Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conclusions</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anderson 2017 [<xref rid="B4-diagnostics-10-01022" ref-type="bibr">4</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient,<break/>35 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN associated with hantavirus infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One month after hantavirus infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Severe, intractable burning limb pain. Allodynia to light touch and hyperalgesia to pinprick in a stocking distribution up to the mid-calf bilaterally</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gabapentin and naproxen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At follow-up 4 months later, his limb pain was only marginally improved</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Apfel 2000 [<xref rid="B5-diagnostics-10-01022" ref-type="bibr">5</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 418 rhNGF<break/>B: 461 placebo<break/>18&#x02013;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rhNGF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
Significant beneficial effect of rhNGF on diabetic polyneuropathy
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aradillas 2015 [<xref rid="B6-diagnostics-10-01022" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case series<break/>level 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33 p,<break/>45.7 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN related to complex regional pain syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.7 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma exchange</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma exchange is effective for patients with severe long-standing complex regional pain syndrome</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Azmi 2015 [<xref rid="B7-diagnostics-10-01022" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49 patients<break/>A: 18 patients with subcutaneous insulin infusion<break/>55.4 &#x000b1; 2.9 years<break/>B: 31 patients with daily insulin injection<break/>49.9 &#x000b1; 3.3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 34.8 &#x000b1; 3.1 years<break/>B: 35.2 &#x000b1; 3.6 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Continuous subcutaneous insulin Infusion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daily insulin injection group showed no significant change, but the subcutaneous insulin infusion group showed an improvement in corneal nerve morphology, consistent with regeneration</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Birnbaum 2018 [<xref rid="B8-diagnostics-10-01022" ref-type="bibr">8</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 patients<break/>~53.6 years<break/>44 &#x000b1; 13 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj&#x000f6;gren&#x02019;s syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49.5 &#x000b1; 23 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain. Eleven patients had stocking-and-glove pain, and 12 patients had non-stocking and-glove pain.<break/>Ten SFN patients (~45%) had neuropathic pain preceding sicca symptoms.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opioid analgesics were prescribed to ~45% of SFN patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj&#x000f6;gren&#x02019;s syndrome SFN had increased frequency of male sex, decreased frequency of multiple antibodies, were frequently treated with opioid analgesics, and could present with nonstocking-and-glove pain</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cao 2015 [<xref rid="B9-diagnostics-10-01022" ref-type="bibr">9</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>36 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN related to idiopathic aquagenic pruritus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~for 3 y after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aquagenic pruritus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Propranolol 10 mg bis in die for 1 month</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atenolol is to be preferred to propranolol, in view of its convenient once-a-day dosing and better side effect profile</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabby 2006 [<xref rid="B10-diagnostics-10-01022" ref-type="bibr">10</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 patients<break/>~49 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain. Symptoms were distal and symmetrical in three patients and generalized in one patient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prednisone, 1 mg/kg for 12 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical improvement occurred 1&#x02013;2 weeks after oral prednisone therapy was initiated.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Greef 2016 [<xref rid="B11-diagnostics-10-01022" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 patients<break/>18&#x02013;80 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCN9A-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, altered temperature sensation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lacosamide, 200 mg bis in die for 8 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lacosamide: a potential treatment option in patients with painful neuropathies, considering the central role of Nav1.7 in pain.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Greef 2016 [<xref rid="B12-diagnostics-10-01022" ref-type="bibr">12</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60 patients<break/>&#x0003e;18 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Idiopathic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, altered temperature sensation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous Immunoglobulins g/kg body<break/>weight over 2&#x02013;4 consecutive days, followed by a maintenance dose of 1 g/kg body weight over 1&#x02013;2 consecutive days given 3 times at a 3-weeks interval</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive findings in SFN after intravenous immunoglobulins</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">De Greef 2019 [<xref rid="B13-diagnostics-10-01022" ref-type="bibr">13</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 patients<break/>~48 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCN-SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain and autonomic dysfunction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lacosamide, 200 mg bis in die for 8 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant effect on pain, general wellbeing, and sleep quality</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favoni 2018 [<xref rid="B14-diagnostics-10-01022" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>45 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-GQ1b antibodies associated with SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2 y after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tingling and burning pain sensation in the arms and legs, with nocturnal exacerbation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adalimumab: 40 mg every day, subcutaneous administration for 1 year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benefit from immunotherapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gaillet 2019 [<xref rid="B15-diagnostics-10-01022" ref-type="bibr">15</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 patients<break/>41&#x02013;62 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj&#x000f6;gren&#x02019;s syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6.5 y after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 months intravenous immunoglobulins infusions, 0.4 g/kg/day for 5 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efficacy of intravenous immunoglobulins treatment for pain relief in Sj&#x000f6;gren&#x02019;s Syndrome-SFN with an improvement of quality of life and sensory testing</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gonz&#x000e1;lez-Duarte 2015 [<xref rid="B16-diagnostics-10-01022" ref-type="bibr">16</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 patients<break/>~54 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prediabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregabalin was initiated at a dose of 75 mg and tapered up to 300 mg bis in die.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improvement of prediabetic neuropathic pain with pregabalin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hilz 2004 [<xref rid="B17-diagnostics-10-01022" ref-type="bibr">17</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 patients<break/>A: 11 patients<break/>B: 11 patients<break/>27.9 &#x000b1; 8 years<break/>C: 25 HC<break/>29 &#x000b1; 10.4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabry related SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzyme replacement therapy A: for 18 months<break/>B: for 23 months<break/>C: placebo<break/>Every 2 weeks, patients were treated with 0.9 to 1.1 mg/kg of agalsidase &#x000df;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzyme replacement therapy with agalsidase beta significantly improves function of C-, A&#x00394;-, and A&#x000df;- nerve fibers and intradermal vibration receptors in Fabry neuropathy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hoeijmakers 2016 [<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case reports</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 patients<break/>~15 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 p idiopathic SFN,<break/>1 p diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~7 y after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Painful itch and tingling of legs, dysautonomia symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gabapentin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate pain relief with treatment with gabapentin in a case.<break/>Treatment with duloxetine, combined with a rehabilitation program, resulted in a marked improvement in daily functioning.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hoitsma 2006 [<xref rid="B19-diagnostics-10-01022" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>39 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">fatigue, neuropathic pain, autonomic<break/>dysfunction, and arthralgia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infliximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN seems not an irreversible disorder; infliximab had good outcomes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hong 2013 [<xref rid="B20-diagnostics-10-01022" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>64 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peripheral neuropathic pain in his both feet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vibration therapy 3 min of vibration<break/>Treatment (total 12 min) at 20 Hz 5 times a week for 4 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The whole-body vibration is a good complementary treatment</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kluding 2012 [<xref rid="B21-diagnostics-10-01022" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 patients<break/>58.4 &#x000b1; 5.98 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.4 &#x000b1; 12.2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 weeks aerobic and strengthening exercises</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exercises improve SFN symptoms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Keohane 2017 [<xref rid="B22-diagnostics-10-01022" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 48 patients<break/>B: 44 patients<break/>18&#x02013;75 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amyloid SNF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Distal-to-proximal sensorimotor neuropathy with autonomic symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: Tafamidis, 20 mg/d for 18 months<break/>B: placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tafamidis delays neurologic progression in early-stage ATTRV30M-FAP.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu 2018 [<xref rid="B23-diagnostics-10-01022" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 patients<break/>41 &#x000b1; 17 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.3 &#x000b1; 6.3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins &#x02265;1 g/kg/4 weeks for &#x02265;3 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins are safe and effective</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MacDonald 2019 [<xref rid="B24-diagnostics-10-01022" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gabapentin (<italic>n</italic> = 69), pregabalin (<italic>n</italic> = 51), duloxetine (<italic>n</italic> = 41), tricyclic agents (<italic>n</italic> = 37), and topical cream (e.g., capsaicin, lidocaine; <italic>n</italic> = 29).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.5% of patients had, at some time, been treated with opioid medications for neuropathic pain.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maino 2017 [<xref rid="B25-diagnostics-10-01022" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6 years after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burning and shooting pain in feet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dorsal Root Ganglion Stimulation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 months post-implantation, the patient continued to experience stimulation-induced paresthesia covering the entire pain area</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mishra 2012 [<xref rid="B26-diagnostics-10-01022" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>22 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6 months after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flupirtine 200 mg 3/d along<break/>with pregabalin 300 mg 2/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduction of pain after flupirtine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morozumi 2008 [<xref rid="B27-diagnostics-10-01022" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 patients<break/>61.8 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins 0.4 g/kg/d for 5 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beneficial after intravenous immunoglobulins therapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Namer 2019 [<xref rid="B28-diagnostics-10-01022" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10 years after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burning pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lacosamide 50 mg orally in the evening for 6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lacosamide reduced pain in SFN</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nevoret 2014 [<xref rid="B29-diagnostics-10-01022" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>60 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic inflammatory demyelinating polyneuropathy SNP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins: 6 doses total, 75 g each + Azathioprine 50 mg bis in die</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Less burning, shooting pains and tingling</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Otis 2013 [<xref rid="B30-diagnostics-10-01022" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 patients<break/>62.5 &#x000b1; 10.9 year</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 12 p cognitive-behavioral therapy<break/>B: 8 p traditional treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cognitive-behavioral therapy reduced pain</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Parambil 2010 [<xref rid="B31-diagnostics-10-01022" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case series</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intractable<break/>neuropathic pain, autonomic dysfunction</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins: 2-g/kg followed by<break/>1-g/kg in 2-weeks, and then received maintenance doses of<break/>1-g/kg every 4-weeks.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins appear to be effective in relieving symptoms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patel 2019 [<xref rid="B32-diagnostics-10-01022" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>31 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCN-SNF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10 years after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Erythromelalgia, painful flushing and burning paresthesia of the proximal extremities</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbamazepine 200 mg bis in die</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carbamazepine reduced pain</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pereira 2016 [<xref rid="B33-diagnostics-10-01022" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case series</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 patients<break/>55 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj&#x000f6;gren&#x02019;s syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~3 years after symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain, Paresthesia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 p corticosteroids,<break/>7 p mycophenolate mofetil,<break/>6patients hydroxychloroquine,<break/>5 patients intravenous immunoglobulins,<break/>4 patients cyclophosphamide,<break/>2 patients other immunosuppressive drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment with corticosteroids with immunosuppressive drugs, as mycophenolate mofetil, had positive results. In contrast, intravenous immunoglobulins had disappointing results</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saito 2015 [<xref rid="B34-diagnostics-10-01022" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>59 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Progressive<break/>pain and hypoesthesia of the right lower back associated with fever and constipation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methylprednisolone 1 g/d for<break/>3 days, followed by prednisolone 40 mg/d</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurological symptoms were effectively relieved with high-dose steroid therapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schiffmann 2006 [<xref rid="B35-diagnostics-10-01022" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 patients<break/>~34 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fabry disease-related SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1; galactosidase 0.2 mg/kg every 2 weeks<break/>followed for 12 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epidermal nerve fiber regeneration did not occur<break/>after enzyme replacement therapy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith 2006 [<xref rid="B36-diagnostics-10-01022" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational study<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 patients<break/>60 &#x000b1; 8.4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 &#x000b1; 31 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rehabilitative exercises</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rehabilitative exercises improved symptoms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tavee 2016 [<xref rid="B37-diagnostics-10-01022" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study<break/>level 2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>115 patients</p></list-item><list-item><label>-</label><p>~46 years,</p></list-item><list-item><label>-</label><p>62 patients IVIG,</p></list-item><list-item><label>-</label><p>12 patients infliximab</p></list-item><list-item><label>-</label><p>14 p IVIG + infliximab</p></list-item><list-item><label>-</label><p>27 patients not treated</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, paresthesia, dysautonomic symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins 2 mg/kg bodyweight for 5 days;<break/>Anti-TNF alpha (infliximab) 5 mg/kg every 4 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beneficial from intravenous immunoglobulins and anti-TNF alpha in symptoms</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uyesugi 2010 [<xref rid="B38-diagnostics-10-01022" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient,<break/>80 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Keloid related SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 years after surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Itching, pain, and allodynia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Botulinum<break/>toxin type A, 100 U, diluted with 5 mL of preservative-free saline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A keloid was treated successfully with botulinum toxin type A.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wakasugi 2009 [<xref rid="B39-diagnostics-10-01022" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient,<break/>40 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paresthesia and burning pain in the distal upper and lower limbs.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins 2 mg for 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins therapy was<break/>immediately and extremely effective</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Waldinger 2011 [<xref rid="B40-diagnostics-10-01022" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case reports</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 patients<break/>~54.5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2.5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unpleasant genital sensations of being on the edge of an orgasm, overactive bladder, absence of erection and ejaculation, or spontaneous ejaculations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TENS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In the male patient, the use of TENS clinically significantly<break/>reduced the symptoms of restless genital syndrome, in a female patient, TENS application had no effect on genital complaints and complaints of overactive bladder syndrome</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Walega 2014 [<xref rid="B41-diagnostics-10-01022" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 patient<break/>53 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burning mouth syndrome-related SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6.5 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bilateral burning pain in the anterior tongue and mucosa of the lips</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Verbal rating scale, Patient&#x02019;s Global Impression of Change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bilateral stellate ganglion blockade</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weintraub 2009 [<xref rid="B42-diagnostics-10-01022" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 90 patients<break/>61.1 &#x000b1; 10.4<break/>B: 104 patients<break/>60.6 &#x000b1; 12.4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetic SNF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: pulsed electromagnetic fields varying intensity and polarity 10&#x02013;30 min session for 2 h maximum, daily, 12 w<break/>B: Sham group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulsed electromagnetic fields at this dosimetry were ineffective in reducing neuropathic pain</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Windebank 2004 [<xref rid="B43-diagnostics-10-01022" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 20 patients, 58.3 &#x000b1; 12.2 years<break/>B: 20 patients<break/>62.2 &#x000b1; 10.7 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;6 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Painful, distal, symmetrical neuropathy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: IGF-I, 0.05 mg/kg twice daily for 6 months<break/>B: placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IGF-I was safe but did not improve symptoms in this 6-month trial</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yuki 2018 [<xref rid="B44-diagnostics-10-01022" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Case report</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 patients,<break/>~27.3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SFN variant of Guillain&#x02013;Barr&#x000e9; syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The three patients developed the symptoms 42, 6 and 11 d, respectively, after symptom onset</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pinprick sensation with hyperesthesia and brush allodynia in a glove-and-stocking<break/>distribution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 p oral prednisolone 40<break/>Mg/d for 5 days<break/>2 patients intravenous immunoglobulins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One patient showed no response to intravenous immunoglobulins but a good response to prednisolone. One patient had no significant improvement<break/>with prednisolone. One patient had a gradual spontaneous recovery</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">van Velzen 2014 [<xref rid="B45-diagnostics-10-01022" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial<break/>level 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: 12 patients<break/>B: 13 patients<break/>~48.6 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sarcoidosis-associated SFN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 years between the current study and the diagnosis of sarcoidosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pain, allodynia, hyperalgesia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A: ARA290, an erythropoietin derivate, intravenous of 2 mg dissolved in 6 mL of normal saline, 3/weeks for 4 weeks<break/>B: placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long-lasting beneficial effects of ARA 290</td></tr></tbody></table><table-wrap-foot><fn><p>Small-fiber neuropathies (SFN), rhNGF recombinant human nerve growth factor, insulin-like growth factor-I (IGF-I), Transcutaneous electrical nerve stimulation (TENS).</p></fn></table-wrap-foot></table-wrap><table-wrap id="diagnostics-10-01022-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">diagnostics-10-01022-t002_Table 2</object-id><label>Table 2</label><caption><p>Rehabilitation programs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Authors</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rehabilitation Program</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Note</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hoeijmakes 2016 [<xref rid="B18-diagnostics-10-01022" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After no results with a pharmacologic approach, the rehabilitation program was added</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hong 2013 [<xref rid="B20-diagnostics-10-01022" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Four bouts of 3 min of vibration treatment (total 12 min) at 20 Hz five times a week for four weeks.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Body vibration reduced acute and long-term pain in diabetics</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kluding 2012 [<xref rid="B21-diagnostics-10-01022" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-week exercise program with both aerobic and strengthening and resistance exercises significantly improved selected measures of peripheral nerve function, with a reduction in pain and neuropathic symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The rehabilitation improved the neuropathic symptoms, nerve function and cutaneous innervation<break/>Rehabilitative exercises were added to the pharmacologic approach in diabetic SFN</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Otis 2013 [<xref rid="B30-diagnostics-10-01022" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cognitive behavioral: each session of 60 min for 11 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For neuropathic pain in diabetic neuropathy</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith 2006 [<xref rid="B36-diagnostics-10-01022" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80 min for 73 weeks with improvement in neuropathic symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rehabilitative program was added to the pharmacologic approach in diabetic SFN</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Waldinger 2011 [<xref rid="B40-diagnostics-10-01022" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transcutaneous electrical nerve stimulation (TENS) in SFN for restless genital syndrome (ReGS) of dorsal nerve penis and in overactive bladder syndrome (OAB).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weintraub 2009 [<xref rid="B42-diagnostics-10-01022" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulsed electromagnetic fields was ineffective in reducing diabetic neuropathic pain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap></floats-group></article>